Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

@article{Diamant2014ExenatideOW,
  title={Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.},
  author={Michaela Diamant and Luc F. Van Gaal and Bruno Guerci and Stephen N. Stranks and Jenny Han and Jaret L. Malloy and Marilyn K. Boardman and Michael E. Trautmann},
  journal={The lancet. Diabetes & endocrinology},
  year={2014},
  volume={2 6},
  pages={464-73}
}
BACKGROUND When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3, exenatide once weekly was compared with insulin glargine (henceforth, glargine) as first injectable therapy. Here, we report the results of the final 3-year follow-up. METHODS DURATION-3 was an open-label randomised trial done between May 13, 2008, and Jan 30, 2012. Patients with type 2 diabetes… CONTINUE READING
44 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…